On October 11, 2017 Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN, a first-in-class, intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, reported that Matt Coffey, Ph.D., President & Chief Executive Officer, will present a corporate overview and outline strategic objectives at the 2017 BIO Investor Forum (Press release, Oncolytics Biotech, OCT 11, 2017, View Source [SID1234520879]).
2017 BIO Investor Forum
Presenter: Matt Coffey, Ph.D., President & Chief Executive Officer, Oncolytics Biotech
Presentation Date and Time: Wednesday, Oct. 18, 2017, 10:00:00 a.m. PT
Location: Westin St. Francis Hotel, Elizabethan C, San Francisco
Dr. Coffey will provide a company overview and highlight recent progress, including randomized phase 2 data in metastatic breast cancer demonstrating a statistically significant increase in overall survival. This progress lead to receiving fast-track designation and conducting a successful End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA), resulting in plans for a single 400-patient phase 3 registration study, the impetus to advance global and/or regional partnership conversations and the objective of relisting on NASDAQ in 2018.
Supported by a fast-track designation, Oncolytics is preparing the most appropriate development path to obtain regulatory approval for REOLYSIN for metastatic breast cancer, an indication with continued and considerable unmet need. In September, the Company announced a successful End-of-Phase 2 Meeting with the FDA for REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer patients. The purpose of the meeting included a discussion of the design of a phase 3 registration study to support a future Biologics License Application (BLA) submission in the U.S.
Oncolytics is pursuing additional immunomodulatory and/or check point inhibitor combinations in collaboration with pharmaceutical companies to further explore the mechanism of action and potential new treatment applications and additional market opportunities. In September, the first patient was treated in the Company’s Phase 1b trial run by Myeloma UK (MUK) called MUK eleven, studying REOLYSIN in combination with Celgene Corporation’s immunomodulatory drugs, Revlimid or Imnovid as a rescue treatment in relapsing myeloma patients.
A live audio link to the webcast session will be available on the Company’s website at View Source It is recommended that listeners log on 10 minutes in advance of a live session to register and download any necessary software. An audio replay will be accessible approximately two hours following the presentation on the Oncolytics website.
About BIO Investor Forum
BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One Partnering meetings.